Parecoxib, valdecoxib, and cardiovascular risk

Circulation. 2005 Jan 25;111(3):249. doi: 10.1161/01.CIR.0000155081.76164.17. Epub 2005 Jan 17.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Cardiovascular Diseases / chemically induced*
  • Cyclooxygenase 2
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors / adverse effects*
  • Humans
  • Isoxazoles / adverse effects*
  • Membrane Proteins
  • Meta-Analysis as Topic
  • Prodrugs / adverse effects*
  • Product Surveillance, Postmarketing
  • Prostaglandin-Endoperoxide Synthases
  • Randomized Controlled Trials as Topic
  • Risk Assessment
  • Sulfonamides / adverse effects*

Substances

  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors
  • Isoxazoles
  • Membrane Proteins
  • Prodrugs
  • Sulfonamides
  • valdecoxib
  • parecoxib
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • Prostaglandin-Endoperoxide Synthases